WO2006054710A1 - 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 - Google Patents
最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 Download PDFInfo
- Publication number
- WO2006054710A1 WO2006054710A1 PCT/JP2005/021272 JP2005021272W WO2006054710A1 WO 2006054710 A1 WO2006054710 A1 WO 2006054710A1 JP 2005021272 W JP2005021272 W JP 2005021272W WO 2006054710 A1 WO2006054710 A1 WO 2006054710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- transit time
- oligosaccharide
- gastrointestinal transit
- water
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 46
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 39
- 230000003449 preventive effect Effects 0.000 title claims abstract description 20
- 208000029742 colonic neoplasm Diseases 0.000 title abstract description 8
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 52
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims abstract description 48
- 229960000511 lactulose Drugs 0.000 claims abstract description 48
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims abstract description 48
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 45
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 45
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 42
- 150000002681 magnesium compounds Chemical class 0.000 claims abstract description 34
- 230000002496 gastric effect Effects 0.000 claims description 156
- 239000003795 chemical substances by application Substances 0.000 claims description 67
- 229920001542 oligosaccharide Polymers 0.000 claims description 55
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 36
- 239000011777 magnesium Substances 0.000 claims description 36
- 229910052749 magnesium Inorganic materials 0.000 claims description 36
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 27
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000004375 Dextrin Substances 0.000 claims description 17
- 229920001353 Dextrin Polymers 0.000 claims description 17
- 235000019425 dextrin Nutrition 0.000 claims description 17
- 239000000835 fiber Substances 0.000 claims description 15
- 239000007857 degradation product Substances 0.000 claims description 14
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 13
- 239000001095 magnesium carbonate Substances 0.000 claims description 13
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 13
- 239000000347 magnesium hydroxide Substances 0.000 claims description 13
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 13
- 235000010449 maltitol Nutrition 0.000 claims description 13
- 239000000845 maltitol Substances 0.000 claims description 13
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 13
- 229940035436 maltitol Drugs 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 150000004804 polysaccharides Chemical class 0.000 claims description 13
- 239000000600 sorbitol Substances 0.000 claims description 13
- 235000010356 sorbitol Nutrition 0.000 claims description 13
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 12
- 244000068988 Glycine max Species 0.000 claims description 12
- 235000010469 Glycine max Nutrition 0.000 claims description 12
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 12
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 12
- 240000008042 Zea mays Species 0.000 claims description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 239000000783 alginic acid Substances 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 229960001126 alginic acid Drugs 0.000 claims description 12
- 150000004781 alginic acids Chemical class 0.000 claims description 12
- 235000005822 corn Nutrition 0.000 claims description 12
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000391 magnesium silicate Substances 0.000 claims description 12
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 12
- 235000019792 magnesium silicate Nutrition 0.000 claims description 12
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 12
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 11
- 229920001100 Polydextrose Polymers 0.000 claims description 11
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 11
- 229940043430 calcium compound Drugs 0.000 claims description 11
- 150000001674 calcium compounds Chemical class 0.000 claims description 11
- 235000013856 polydextrose Nutrition 0.000 claims description 11
- 239000001259 polydextrose Substances 0.000 claims description 11
- 229940035035 polydextrose Drugs 0.000 claims description 11
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 11
- RFCVXVPWSPOMFJ-UHFFFAOYSA-N 2-[(2-azaniumyl-3-phenylpropanoyl)amino]-4-methylpentanoate Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-UHFFFAOYSA-N 0.000 claims description 10
- KSRQDWNGXKYIDO-UHFFFAOYSA-N difructose anhydride III Natural products O1C2C(O)C(CO)OC2(CO)OCC21OC(CO)C(O)C2O KSRQDWNGXKYIDO-UHFFFAOYSA-N 0.000 claims description 10
- 230000002706 hydrostatic effect Effects 0.000 claims description 10
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 9
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 2
- 201000011061 large intestine cancer Diseases 0.000 claims 1
- 230000013872 defecation Effects 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 35
- 206010010774 Constipation Diseases 0.000 abstract description 27
- 239000010794 food waste Substances 0.000 abstract description 26
- 206010012735 Diarrhoea Diseases 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 6
- 206010020710 Hyperphagia Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 235000020830 overeating Nutrition 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000003028 elevating effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 40
- 235000012054 meals Nutrition 0.000 description 31
- 230000035622 drinking Effects 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- 206010000060 Abdominal distension Diseases 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- 230000037213 diet Effects 0.000 description 13
- 230000009931 harmful effect Effects 0.000 description 13
- 238000004904 shortening Methods 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 150000002482 oligosaccharides Chemical class 0.000 description 9
- -1 palatinose oligosaccharide Chemical class 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000020845 low-calorie diet Nutrition 0.000 description 8
- 235000014214 soft drink Nutrition 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229960005069 calcium Drugs 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000001465 calcium Nutrition 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000000832 lactitol Substances 0.000 description 5
- 235000010448 lactitol Nutrition 0.000 description 5
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 5
- 229960003451 lactitol Drugs 0.000 description 5
- 239000008141 laxative Substances 0.000 description 5
- UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000161 Locust bean gum Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 235000010420 locust bean gum Nutrition 0.000 description 4
- 239000000711 locust bean gum Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020575 Hyperammonaemia Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 229940125722 laxative agent Drugs 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000000152 swallowing effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000009748 deglutition Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000010459 dolomite Substances 0.000 description 2
- 229910000514 dolomite Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000036115 Faecal volume increased Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- YXZGFZHOTFZCFU-UHFFFAOYSA-J dicalcium;chloride;phosphate Chemical compound [Cl-].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O YXZGFZHOTFZCFU-UHFFFAOYSA-J 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021066 non-refined food Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention prevents food intake from staying in the gastrointestinal tract, particularly the lower gastrointestinal tract (large intestine) for a long time, and shortens the time until it is discharged from the body without causing stool without anxillary action.
- the present invention relates to a technology that suppresses adverse effects on the human body, particularly the large intestine, caused by harmful spoilage products.
- Burkitt et al. Have a small amount of refined dietary fiber! /, Eat a meal! /, Westerners are likely to have a longer time for food residues to pass through the digestive tract, such as colon cancer. The incidence of large bowel disease is high, while dietary fiber is high! Eating unrefined food! / The short transit time of gastrointestinal tract indicates that Africans rarely have colon disease.
- Cummings et al. Found that there was an inverse correlation between colorectal cancer incidence and defecation volume in a survey of 23 regions in the world. In the Burkitt et al. Study, there is an inverse correlation between the amount of defecation and transit time. For this reason, it is considered that the greater the amount of defecation, the shorter the passage time in the digestive tract and the less likely it is to develop colorectal cancer.
- constipation is the frequency of defecation, for example, if there is no regular defecation, or how many days in a week there is no defecation.
- constipation is not diagnosed with the awareness of food residue passage time in the digestive tract.
- Defecation is defined as the contents of excreta that are congested in the intestinal tract when the burden continues beyond the capacity of the gastrointestinal tract. (Dr. Mitsuo Koda, “If you skipped breakfast, you'll get this.” Shunjusha).
- the state and extent of content congestion in the gastrointestinal tract cannot be estimated from mere defecation frequency, which has been used to diagnose constipation in the past, and it is necessary to directly check the state and extent of congestion.
- constipation drugs or laxatives may not be effective in treating constipation patients, that is, increasing the frequency of defecation, but it does not necessarily increase the digestive and maximum gastrointestinal transit times of food residues that remain for a long time. It cannot be said that it is effective for shortening.
- the use of constipation drugs or laxatives by healthy individuals who are not constipated may cause discomfort such as abdominal distension or weakness due to indigestion. Often accompanied. It is caused by food residues staying in the gastrointestinal tract for a long time by healthy individuals to improve their health by quickly shortening the gastrointestinal transit time and the maximum gastrointestinal transit time without these symptoms.
- No gastrointestinal transit time improving agent or maximum gastrointestinal transit time improving agent capable of preventing various diseases has been known.
- indigestible saccharides and dietary fiber are not digested in the upper digestive tract and are not digested in the lower digestive tract.
- indigestible oligosaccharides have been studied in detail for the action of proliferating colonic bifidobacteria and making the intestinal environment acidic by the action of the short-chain fatty acid produced to improve the intestinal flora.
- the number of bifidobacteria in the large intestine is reduced due to constipation or for some reason, by increasing the number of bifidobacteria by administration of oligosaccharide, the pH in the intestine is lowered and other harmful intestinal bacteria By suppressing the growth and preparing the intestinal environment, it is interpreted that the reduction of harmful spoilage products in the intestine can improve the convenience.
- latitol or lactulose which are indigestible saccharides, reduce ammonia produced by harmful intestinal bacteria, so that they can be used as drugs for improving bowel function and treating symptoms associated with hyperammonemia.
- hyperammonemia the ability to take lactulose powder with a pure content of 97% or more, 19.5 to 39 g a day for adults, 100% lactitol powder with a pure content, 18 to 36 g a day for adults 3 times Divide into two doses. Ratathitol and lactulose are administered in such high doses in people with impaired bowel function, who are prone to colon polyps, and in patients with hepatic encephalopathy due to hyperammonemia.
- magnesium oxalate marketed as a laxative
- 2g per day before or during meals take 3 doses or take 1 dose before going to bed.
- Magnesium oxide 2g is equivalent to 1160 mg of magnesium.
- the strong abdominal action causes side effects such as abdominal fullness and weakness after defecation due to indigestion. hard.
- Non-constipated gastrointestinal transit time or the maximum gastrointestinal transit time can be improved in healthy individuals with normal defecation rather than loose stool, without any deglutition or side effects.
- the dosage of magnesium is not indicated in the Japanese Pharmacopoeia.
- Japanese Patent Application Laid-Open No. 2001-48792 describes a laxative containing an active magnesium oxalate having a specific surface area (BET) force of 21 m 2 Zg or more as an active ingredient.
- activated magnesium oxide 2.4 g Zl00 ml solution was taken to 70 ml per day (974 mg as magnesium) to five monitors, and the laxative effect was confirmed.
- a solution of activated magnesium oxide 2.4 g Zl00 ml, 100 ml of oligosaccharide solution and 40 ml of drinking water is prepared, and 150 ml per day (870 mg as magnesium) is prepared for five monitors. The majesty effect has been confirmed.
- the pharmaceutical dosage is applied only for the duration of the disease by the patient for treatment and should not be applied if a healthy person takes it daily for disease prevention purposes.
- An object of the present invention is to increase the speed and strength of a healthy person who is not constipated, so that the food residue staying in the extinguishing tube for a long time due to overeating or the like does not cause a loose stool without a swallowing action.
- the purpose is to promote the maintenance of health by reducing the harmful effects of harmful spoilage products in the intestines on the human body.
- the present inventor has one or more selected from among non-constipated healthy individuals who have regular stool and are indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compound. Shorten the maximum gastrointestinal transit time and gastrointestinal transit time, which are prolonged due to overeating, etc., without unpleasant side effects such as bloating, vaginal action, loose stool, etc. by using lactulose and acid ⁇ magnesium together The present invention has been completed.
- the present invention relates to the following technique.
- Item 1 A maximum digestive tract transit time improving agent characterized by containing at least one kind of hardly digestible saccharide, low-viscosity water-soluble dietary fiber, and magnesium compound.
- Item 2 Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, ratatosucrose, furata-oligosaccharide, isomaltoligosaccharide, xylooligosaccharide, palatinose oligosaccharide, difructose anhydride III, sorbitol, maltitol, ratathitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is resistant to digestion dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn It is at least one selected from the group consisting of one fiber, and at least a group force consisting of magnesium compound power magnesium oxide, magnesium hydroxide, magnesium silicate, and magnesium carbonate power is also selected.
- Item 3 The maximum gastrointestinal transit time improving agent according to Item 2, comprising lactulose and magnesium oxide.
- Item 4 The maximum gastrointestinal transit time improving agent according to any one of Items 1 to 3, further comprising a calcium compound.
- Item 5 A gastrointestinal transit time improver containing lactulose and magnesium oxide.
- Item 6 The gastrointestinal transit time improving agent according to Item 5, further comprising a calcium compound.
- Item 7 A preventive agent for colorectal cancer comprising lactulose and magnesium oxide.
- Item 8 The colon cancer preventive agent according to Item 7, further comprising a calcium compound.
- Item 9 Reduced maximum gastrointestinal transit time characterized by oral administration of an effective amount to improve the maximum gastrointestinal transit time of any one of indigestible saccharide, low-viscosity water-soluble dietary fiber and magnesium compound How to make.
- Item 10 Oral dosage power per day for indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compounds is 0.8 to 6 g, lg to 10 g, and 40 mg to 600 mg in terms of magnesium, respectively.
- Item 10. A method for reducing the maximum gastrointestinal transit time according to Item 9.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium si
- Item 12 A method for preventing colorectal cancer, comprising orally administering an effective amount for preventing colorectal cancer of any one of indigestible saccharides, low-viscosity water-soluble dietary fiber and magnesium compound.
- Item 13 Daily dosage of indigestible saccharides, low-viscosity water-soluble dietary fiber, and magnesium compounds per day for adults 0.8 g to 6 g, lg to 10 g, and 40 mg to 600 mg in terms of magnesium Item 13.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium si
- Item 15 A method of reducing gastrointestinal transit time characterized by orally administering an amount effective for improving the gastrointestinal transit time of lactulose and magnesium oxide.
- Item 16 Oral dosage power per day for adults of lactulose and magnesium oxalate: 0.8 g to 6 g, and 40 mg to 600 mg in terms of magnesium, respectively. How to lower.
- Item 17 Use of any one of indigestible saccharides, low-viscosity water-soluble food fibers and magnesium compounds to reduce the maximum gastrointestinal transit time.
- Indigestible saccharides are lactulose, galatato-oligosaccharides, raffinose, stachyose, latatosucrose, furato-oligosaccharides, isomalt-oligosaccharides, xylo-oligosaccharides, palatinose-oligosaccharides, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one selected from the group consisting of one force, magnesium compound power magnesium oxide, hydroxide Item 18. The use according to Item 17, wherein the group power of magnesium, magnesium silicate, and
- Item 19 Use of one of the hard-to-digest saccharides, low-viscosity water-soluble dietary fiber, and magnesium compound to prevent colorectal cancer.
- Indigestible saccharides are lactulose, galatato-oligosaccharide, raffinose, stachyose, latatosucrose, furato-oligosaccharide, isomalt-oligosaccharide, xylo-oligosaccharide, palatinose-oligosaccharide, difructose anhydride III, sorbitol, maltitol, lactitol, reduced
- a group power of palatinose and reduced hydrostatic strength is at least one selected, and low-viscosity water-soluble dietary fiber is indigestible dextrin, guagam degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber It is at least one kind selected from the group consisting of one power and is characterized by at least one kind selected from the group power consisting of magnesium compound power magnesium hydroxide, magnesium hydroxide, magnesium
- Item 21 Use of lactulose and magnesium oxide to reduce gastrointestinal transit time.
- improvement of the maximum gastrointestinal tract passage time means a reduction in the maximum gastrointestinal tract passage time, and is synonymous with the improvement of stool.
- the maximum gastrointestinal transit time and gastrointestinal transit time are shortened and generated from food residues without causing unpleasant side effects such as abdominal fullness, axillary action, and loose stool, particularly fullness. It can suppress the adverse effects on human body due to harmful spoilage products, and can promote the maintenance or promotion of health such as prevention of colorectal cancer. That is, in the present invention, the gastrointestinal transit time can be set to about 17 hours to 70 hours and the maximum gastrointestinal transit time can be set to about 25 hours to 100 hours without feeling abdominal fullness. Furthermore, the maximum gastrointestinal transit time and the range between meals (standard deviation) of the gastrointestinal transit time can be reduced to prevent food residues from staying in the gastrointestinal tract for an extremely long time.
- low-viscosity water-soluble dietary fiber examples include indigestible dextrin, guar gum degradation product, polydextrose, water-soluble soybean polysaccharide, low-molecular alginic acid, and water-soluble corn fiber. Among these, indigestible dextrin or guar gum degradation product is preferable. These low-viscosity water-soluble dietary fibers can be used alone or in combination of two or more, and the intake of healthy adults who are not constipated is preferably lg to 10 g per day. I like it!
- a calcium compound can be further blended.
- Calcium compounds are preferred because they have the effect of alleviating the tendency of loose stool due to magnesium oxide.
- Examples of the calcium compound used in the present invention include calcium carbonate, calcium chloride calcium phosphate, calcium phosphate, calcium lactate, calcium dulconate, calcined shellfish calcium, eggshell strength lucium, dolomite and the like.
- the daily intake of calcium compounds is preferably 10 mg to 1200 mg as the amount of calcium.
- the maximum gastrointestinal transit time improving agent, the gastrointestinal transit time improving agent and the colorectal cancer preventive agent containing a combination of lactulose and magnesium oxide include other indigestible saccharides, low viscosity water-soluble Dietary fiber and a magnesium compound can also be blended.
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention include compositions to be administered orally.
- it includes forms such as pharmaceuticals, foods, and supplements.
- the dosage unit form of the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention is not particularly limited as long as it is suitable for oral administration, and can be appropriately selected according to the purpose of administration. . Specific examples include oral preparations such as tablets, coated tablets, powders, granules, capsules, solutions, pills, suspensions, and emulsions. These administration agents are produced by a formulation method generally known in this field.
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention are used in a food form, the indigestible saccharide, the low-viscosity water-soluble dietary fiber, or the magnesium compound If necessary, it can be prepared by an ordinary method in combination with an edible carrier, food material, food additive or the like according to its form.
- a food form it can be used as a liquid food such as a beverage, or a solid food such as a tablet, granule, or a chewable tablet. It can also be used as a semi-solid food such as yogurt. It can also be used as health foods, functional foods, foods for specified health use, functional foods for nutrition, foods for the sick, etc.
- Specific food forms include juices, soft drinks, liquid drinks such as tea; powdered drinks such as powdered juice and powdered soup; chocolates, candy, chewing gum, ice cream, jelly, cookies, biscuits, corn flakes, chiyu Confectionery such as tablet tablets, film sheets, wafers, gummi, rice crackers, buns; seasonings such as dressings and sauces; breads, rice cakes, konjac, kneaded products (kamaboko, etc.), sprinkles, oral sprays, lozenges, etc. Can be mentioned. Further, as an additive, live bacteria such as lactic acid bacteria or dead bacteria, other probiotic materials, vitamins, herbal medicines, herbs and other plants themselves or extracts may be blended.
- Examples of the carrier constituting the food include sugar alcohols such as xylitol and erythritol, crystalline cellulose, lactose, sucrose, glucose, starch, carbonates, phosphates and other enhancers, gelatin, alginic acid, Xanthan gum, cellulose, hydroxypropyl cellulose, methylcellulose, carrageenan, pullulan, pectin and other binders, sucrose fatty acid ester, sorbitan fatty acid ester, enzyme-treated lecithin, enzyme-decomposed lecithin, saponin Antioxidants such as ascorbic acid and tocopherol, acidulants such as lactic acid, citrate, darconic acid, glutamic acid, fortifiers such as vitamins, amino acids, lactate, citrate, dalconate, diacid Fluidizing agents such as sucrose, lubricants such as sucrose fatty acid esters, stearates, Kurarosu, acesulfame
- the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention are used in the form of pharmaceuticals, the indigestible saccharide, the low-viscosity water-soluble dietary fiber, or magnesium
- the compound can be prepared by a usual method in combination with a pharmaceutically acceptable carrier, pharmaceutical material, additive and the like according to the form, if necessary.
- the pharmaceutical form include solid preparations such as liquids, tablets, granules, fine granules, and powders, and orally administrable forms such as capsules containing the liquid or solid preparations.
- Examples of the pharmaceutically acceptable carrier include lactose, sucrose, sodium chloride salt, glucose, starch, calcium carbonate, kaolin, crystalline cellulose, kalic acid, methylcellulose, glycerin, sodium alginate, gum arabic, and talc. , Calcium monohydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, potassium dihydrogen phosphate, calcium dihydrogen phosphate, sodium dihydrogen phosphate, calcium sulfate, calcium lactate, strength cocoa butter, etc.
- Excipients simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, cross polyvinyl pyrrolidone, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropylmethyl cell Loin, hydroxy E chill cellulose, Kano levo carboxy vinyl Honoré polymer, crystal cellulose, powdered cellulose, microcrystalline cellulose 'carmellose sodium, carboxy methylate Roh receptacle Honoré loin, shellac, methylcellulose, E chill cellulose, potassium phosphate, ⁇ Labia gum powder, pullulan, dextrin, corn starch, alpha-monified starch, hydroxypropyl starch, gelatin, xanthan gum, tragacanth, tragacanth powder, macaque glue, dry starch, sodium alginate, agar powder, laminaran powder, bicarbonate Disintegrating agents such as sodium, calcium
- the tablets can be made into tablets with ordinary coatings as necessary, for example, sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, multilayer tablets and the like.
- Capsules are prepared by mixing the active ingredient with the various carriers exemplified above and filling hard gelatine capsules, soft capsules, and the like.
- the liquid preparation may be an aqueous or oily suspension, solution, syrup or elixir, and is prepared according to a conventional method using ordinary carriers, additives and the like.
- thickening polysaccharides and dietary fibers can be blended to such an extent that the effect of improving gastrointestinal transit time is not diminished.
- fragrances include heart force oil, eucalyptus oil, keihi oil, wikiyo oil, timber oil, orange oil, lemon oil, rose oil, funole flavor, mint flavor, peppermint powder, dl-menthol, 1 Mentor, etc.
- the administration target of the maximum gastrointestinal transit time improving agent, gastrointestinal transit time improving agent and colorectal cancer preventive agent of the present invention is a healthy person and anxious about the condition of the stomach.
- the person who is concerned about the condition of the stomach is a healthy person who regularly has stool that is not diagnosed as constipation according to the diagnostic criteria for constipation, and the stool is stiffer than the person with normal stool, and the daily The amount of bowel movements is small. Therefore, the subject of administration of the present invention does not include those with constipation.
- those who are worried about the condition of the stomach are those whose defecation frequency per day is 0.5 or more and less than 1.0, and those who are normal in the state of defecation are defecation frequency per day However, those who have constipation are those who regularly defecate and whose defecation frequency per day is less than 0.43.
- a high calorie diet means a caloric intake per day for adults of 35 kcal or more or approximately 2100 kcal or more per kg of body weight.
- the method devised by Hinton et al. was adopted as a method of examining the time to defecation, that is, the time to pass through the digestive tract. Specifically, multiple X-ray contrast-enhanced markers are taken with meals, and the time taken for the marker to be excreted (ti) and the marker contained in the excreted stool based on the X-ray image of the collected stool The number (xi) was determined and the gastrointestinal transit time was calculated from the following formula. Gastrointestinal transit time refers to the average value until several ethasographic contrast markers taken simultaneously are excreted.
- locust bean gum and sirium beet fiber which are considered to have a feasibility improving effect as a dietary fiber, no statistically significant reduction in gastrointestinal transit time and maximum gastrointestinal transit time is observed.
- Katsutsu Locust bean gum and psyllium are water-soluble dietary fibers but have the property of increasing viscosity when dissolved in water.
- Beet fiber is an insoluble dietary fiber. Locust bean gum and psyllium were observed to increase the average defecation volume, but there was no effect of shortening the gastrointestinal transit time and the maximum gastrointestinal transit time.
- the gastrointestinal transit time was shortened while drinking this product to 12 out of 13 people, except for No. 1 person.
- the thirteen pre-drinking gastrointestinal transit time was about 37 hours to about 124 hours, but decreased to about 23 hours to about 70 hours while drinking this product. Compare with the average of 13 people As a result, the gastrointestinal transit time before drinking this product was 67.9 hours, while it was 43.9 hours during drinking, improving the gastrointestinal transit time at a statistical significance level of less than 1%. .
- the maximum gastrointestinal transit time was shortened while taking this product to 12 of 13 people, except for No. 6, one person.
- the maximum gastrointestinal transit time before drinking for about 13 people was about 52 hours to about 151 hours. During drinking this product decreased to about 42 hours to about 98 hours. Comparing the average value of 13 people, the maximum gastrointestinal transit time before drinking this product was 85.2 hours, but it was 63.9 hours while drinking this product, and the statistical significance level was less than 1% The maximum gastrointestinal transit time was improved.
- the average defecation amount per day for 13 subjects increased from 76.2 g before drinking to 117.3 g during drinking at a statistical significance level of less than 5%.
- the shortening of the gastrointestinal transit time and the maximum gastrointestinal transit time of 13 subjects was more prominent in subjects with longer time before drinking.
- no side effects such as diarrhea, loose stool, and abdominal bloating or discomfort were observed. Therefore, this product stays in the gastrointestinal tract for a long time without any pain or discomfort caused by the armpit action! / Reduces the passage time of sour food residues.
- the amount of total spoilage product, the amount of ammonia, the pH, and the amount of water in the stool Nos. 1 to 7 in which the stool samples could be stored at low temperature immediately after defecation were measured.
- phenol, p-cresol, 4E-phenol, indole and skatole were quantified using a gas chromatograph, and the total of these was used as the total spoilage product amount.
- Table 3 shows the total amount of spoilage products and the measurement results of ammonia.
- the pH and water content of feces are shown in Table 4.
- the statistical significance level decreased to 54.5 g, less than 1%.
- the average value of the amount of Ammonia in 7 subjects decreased from 972 gZg before drinking to 593 gZg during drinking at a statistical significance level of less than 1%. From these results, it was shown that the present invention can be expected to prevent colorectal cancer.
- the effect of shortening the gastrointestinal transit time and the maximum gastrointestinal transit time by oral administration of lactulose and magnesium oxide is different from the effect of improving constipation by dietary fiber and oligosaccharides.
- calculating the change in the total amount of spoilage products before and during drinking around the dry weight of feces after removing water the total amount of spoilage products decreased, and the dilution effect due to an increase in the water content in a single stool Turned out not to be.
- a solution having the composition shown in Table 6 was prepared. After the preparation, heat sterilization was performed at 95 ° C for 2 minutes, and 1 OOml was filled into a bottle that could be sealed at a temperature of 85 ° C or higher. * Tightened and cooled in running water. For each 100ml of this product, 2g of resistant sugar and 336mg of magnesium can be ingested.
- the high-calorie diet is 4 retort curry (221kcal.), 5 packed rice (302kcal.) And 80g serial (150kcal.) Per day, totaling 2694kcal.
- the low-calorie diet is 2498 retorts, 3 packs of rice and 40g of cereal per serving, for a total of 1498kcal.
- the high-calorie diet weighs 1920g and the low-calorie diet weighs 1060g.
- a jelly having the following composition was prepared by a conventional method.
- the raw material was heated and dissolved in purified water, sterilized by heating at 95 ° C for 2 minutes, filled with lOOg in a plastic cup, sealed with aluminum, and then cooled in running water.
- This lOOg contains 250mg of magnesium.
- Powdered tea having the following composition was prepared by a conventional method. Each raw material was prepared in a granular form by a fluidized bed granulator. When 5g of this product is dissolved in 180ml of hot water and consumed, 2g of indigestible dextrin and 1.5g of difructose anhydrate III can be ingested.
- Tablets having the following composition were prepared by a conventional method. After the preparation, the tablets were tableted using a rotary continuous tableting machine so that the weight per tablet was 320 mg. By taking 4 to 10 tablets of this product per day, you can ingest about 0.85g to 2.lg as indigestible saccharide and about 186mg to 464mg as magnesium. [0071] Ingredient Compounding amount (% by weight)
- a soft drink having the following composition was prepared by a conventional method. After the preparation, heat sterilization was carried out at 95 ° C for 2 minutes, 160 g of which was filled in a tin can at a temperature of 90 ° C or higher, and then cooled in running water. Per 1 can (160g) of this product, 5.3g of indigestible sugar can be ingested.
- a jelly having the following composition was prepared by a conventional method. This lOOg contains 255 mg magnesium and 50 mg calcium.
- the present invention can be used in fields where the maximum gastrointestinal tract passage time and the digestive tract passage time are required to be shortened. In addition, the present invention can be used in fields that require prevention of colorectal cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05806886A EP1825857A1 (en) | 2004-11-22 | 2005-11-18 | Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
JP2006545174A JPWO2006054710A1 (ja) | 2004-11-22 | 2005-11-18 | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 |
US11/791,166 US20080044493A1 (en) | 2004-11-22 | 2005-11-18 | Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-368458 | 2004-11-22 | ||
JP2004368458 | 2004-11-22 | ||
JP2005134745 | 2005-05-06 | ||
JP2005-134745 | 2005-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006054710A1 true WO2006054710A1 (ja) | 2006-05-26 |
Family
ID=36407246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/021272 WO2006054710A1 (ja) | 2004-11-22 | 2005-11-18 | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080044493A1 (ja) |
EP (1) | EP1825857A1 (ja) |
JP (1) | JPWO2006054710A1 (ja) |
WO (1) | WO2006054710A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009167172A (ja) * | 2007-12-21 | 2009-07-30 | Nutri Kk | 整腸及び/又は便通改善のための組成物 |
JP2014532725A (ja) * | 2011-11-06 | 2014-12-08 | エスエスブイ セラピューテクス,リミティド ライアビリティ カンパニー | 下剤および食品サプリメントとしての濃縮プルーンおよびプレバイオティクスの製剤 |
WO2015076164A1 (ja) * | 2013-11-19 | 2015-05-28 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
WO2016042831A1 (ja) * | 2014-09-18 | 2016-03-24 | 協和化学工業株式会社 | 大腸の検査または手術のための処置用製剤 |
KR20220120170A (ko) * | 2021-02-23 | 2022-08-30 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
GB2447067A (en) * | 2007-02-20 | 2008-09-03 | Branko R Babic | Alteration of osmotic gradients by polyhydroxy compounds |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
BE1019158A5 (fr) * | 2009-01-19 | 2012-04-03 | Univ Liege | Procede de production d'une composition, composition et utilisation de celle-ci comme additif alimentaire. |
SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
FR2971123B1 (fr) * | 2011-02-08 | 2013-11-22 | Solvay | Galactofructose pour son effet regulateur du transit intestinal |
JP2014224080A (ja) * | 2013-05-17 | 2014-12-04 | 協和化学工業株式会社 | 大腸の検査または手術のための処置剤 |
US10806743B1 (en) * | 2017-05-12 | 2020-10-20 | Braintree Laboratories, Inc. | Method of administering lactitol to reduce plasma concentration of lactitol |
IT202100002204A1 (it) * | 2021-02-02 | 2022-08-02 | Foodar Advanced Res S R L | Composizione per il trattamento della disfagia |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62220169A (ja) * | 1986-03-18 | 1987-09-28 | Yakult Honsha Co Ltd | 流動性食品 |
JPS6363366A (ja) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | 整腸増進健康食品 |
JPH01319421A (ja) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | 食物繊維不足者の便秘改善,便通促進,便性改善用成型物 |
JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
JPH05255097A (ja) * | 1992-01-24 | 1993-10-05 | Miyarisan Seibutsu Igaku Kenkyusho:Kk | 液状組成物 |
JP2000050843A (ja) * | 1998-08-10 | 2000-02-22 | Morinaga Milk Ind Co Ltd | カルシウム剤、その製造方法、及びカルシウム剤を含 有する食品 |
JP2001097868A (ja) * | 1999-09-30 | 2001-04-10 | Nippon Beet Sugar Mfg Co Ltd | 排便促進組成物 |
JP2002051731A (ja) * | 2000-08-11 | 2002-02-19 | Toyo Shinyaku:Kk | 麦若葉由来の素材を含む便秘改善食品 |
JP2002104980A (ja) * | 2000-09-25 | 2002-04-10 | Takama:Kk | 消化器系運動亢進剤 |
JP2002223726A (ja) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | 美容食品 |
JP2004137194A (ja) * | 2002-10-17 | 2004-05-13 | Fancl Corp | 便通改善組成物 |
JP2004166639A (ja) * | 2002-11-21 | 2004-06-17 | Tsuboichi Seicha Honpo:Kk | ケール茶 |
JP2004224777A (ja) * | 2003-01-27 | 2004-08-12 | Hayashibara Biochem Lab Inc | 抗便秘組成物 |
JP2004292356A (ja) * | 2003-03-27 | 2004-10-21 | Rohto Pharmaceut Co Ltd | 瀉下用製剤 |
-
2005
- 2005-11-18 EP EP05806886A patent/EP1825857A1/en not_active Withdrawn
- 2005-11-18 US US11/791,166 patent/US20080044493A1/en not_active Abandoned
- 2005-11-18 WO PCT/JP2005/021272 patent/WO2006054710A1/ja not_active Application Discontinuation
- 2005-11-18 JP JP2006545174A patent/JPWO2006054710A1/ja active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62220169A (ja) * | 1986-03-18 | 1987-09-28 | Yakult Honsha Co Ltd | 流動性食品 |
JPS6363366A (ja) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | 整腸増進健康食品 |
JPH01319421A (ja) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | 食物繊維不足者の便秘改善,便通促進,便性改善用成型物 |
JPH05255097A (ja) * | 1992-01-24 | 1993-10-05 | Miyarisan Seibutsu Igaku Kenkyusho:Kk | 液状組成物 |
JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
JP2000050843A (ja) * | 1998-08-10 | 2000-02-22 | Morinaga Milk Ind Co Ltd | カルシウム剤、その製造方法、及びカルシウム剤を含 有する食品 |
JP2001097868A (ja) * | 1999-09-30 | 2001-04-10 | Nippon Beet Sugar Mfg Co Ltd | 排便促進組成物 |
JP2002051731A (ja) * | 2000-08-11 | 2002-02-19 | Toyo Shinyaku:Kk | 麦若葉由来の素材を含む便秘改善食品 |
JP2002104980A (ja) * | 2000-09-25 | 2002-04-10 | Takama:Kk | 消化器系運動亢進剤 |
JP2002223726A (ja) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | 美容食品 |
JP2004137194A (ja) * | 2002-10-17 | 2004-05-13 | Fancl Corp | 便通改善組成物 |
JP2004166639A (ja) * | 2002-11-21 | 2004-06-17 | Tsuboichi Seicha Honpo:Kk | ケール茶 |
JP2004224777A (ja) * | 2003-01-27 | 2004-08-12 | Hayashibara Biochem Lab Inc | 抗便秘組成物 |
JP2004292356A (ja) * | 2003-03-27 | 2004-10-21 | Rohto Pharmaceut Co Ltd | 瀉下用製剤 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009167172A (ja) * | 2007-12-21 | 2009-07-30 | Nutri Kk | 整腸及び/又は便通改善のための組成物 |
JP2016172761A (ja) * | 2007-12-21 | 2016-09-29 | ニュートリー株式会社 | 整腸及び/又は便通改善のための組成物 |
JP2014532725A (ja) * | 2011-11-06 | 2014-12-08 | エスエスブイ セラピューテクス,リミティド ライアビリティ カンパニー | 下剤および食品サプリメントとしての濃縮プルーンおよびプレバイオティクスの製剤 |
WO2015076164A1 (ja) * | 2013-11-19 | 2015-05-28 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
JP5892295B2 (ja) * | 2013-11-19 | 2016-03-23 | 日清オイリオグループ株式会社 | 粉末油脂組成物およびその製造方法 |
WO2016042831A1 (ja) * | 2014-09-18 | 2016-03-24 | 協和化学工業株式会社 | 大腸の検査または手術のための処置用製剤 |
KR20220120170A (ko) * | 2021-02-23 | 2022-08-30 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
KR102614356B1 (ko) | 2021-02-23 | 2023-12-14 | 주식회사 핏나인코리아 | 천연물질을 유효성분으로 포함하는 배변활동 개선용 다이어트 식품 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20080044493A1 (en) | 2008-02-21 |
EP1825857A1 (en) | 2007-08-29 |
JPWO2006054710A1 (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006054710A1 (ja) | 最大消化管通過時間改善剤、消化管通過時間改善剤及び大腸癌予防剤 | |
JP6882931B2 (ja) | プレバイオティック製剤および使用方法 | |
RU2607351C1 (ru) | Композиции для баланса кишечной микробиоты, их получение и применение | |
KR101947720B1 (ko) | 위 및 결장 조제물 및 이의 제조 및 사용 방법 | |
JP4162147B2 (ja) | アレルギー抑制剤 | |
WO2013032744A2 (en) | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum | |
AU2005290262A1 (en) | Compositions having body fat reducing function and food and drink containing the same | |
JP3065648B2 (ja) | L―糖緩下薬 | |
CN102138594A (zh) | 一种具有调节肠道菌群功能的复方沙棘茶制剂 | |
JPH05255097A (ja) | 液状組成物 | |
NO320546B1 (no) | Prebiotiske kombinasjonsprodukter | |
US20100183774A1 (en) | Glucosamine as a food and beverage additive | |
BE1025428B1 (nl) | Voedingssupplement en gebruiken daarvan | |
JP2007131541A (ja) | 成長ホルモン分泌促進剤 | |
JP6650728B2 (ja) | ダイエット用の製剤 | |
JPWO2008053984A1 (ja) | アロエおよび寒天を含有した健康食品 | |
WO2009113594A1 (ja) | 機能性消化管障害予防・改善剤および食品 | |
CN112912070A (zh) | 夜间多尿的治疗或预防剂 | |
EP4353238A1 (en) | Composition for improving intestinal microbial population comprising galactose | |
WO2010104175A1 (ja) | 経口用組成物 | |
US20070259094A1 (en) | N-acetylglucosamine as a food and beverage additive | |
JP7090849B2 (ja) | 肝機能改善用組成物及び肝機能改善用食品組成物 | |
JP7057039B2 (ja) | 認知症の予防又は改善用剤及びそれを含む組成物 | |
JPH11147828A (ja) | コレステロール及び脂質吸収阻害剤 | |
JP7063514B2 (ja) | 起立性低血圧の予防又は改善用剤及びそれを含む組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006545174 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11791166 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806886 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806886 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005806886 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11791166 Country of ref document: US |